Clinical performance of a noninvasive melanoma rule-out test across Fitzpatrick skin types

Le résumé fourni par la source

To the Editor: Numerous studies suggest that melanoma in individuals with higher Fitzpatrick skin types (FST) is more likely to present at an advanced stage and result in higher mortality.1 A noninvasive genomic rule-out test assessing gene expression of LINC00518 and PRAME has been introduced to help augment detection of melanoma at an early stage while reducing the number of biopsies performed for benign pigmented lesions that simulate melanoma.2,3 Clinical validation using histopathologic consensus diagnoses as a reference standard demonstrated the test has a ≥99% negative predictive value (NPV), indicating that a lesion that tests negative is unlikely to be a melanoma.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.